{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:42:27Z","timestamp":1780630947480,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1097\/maj.0b013e31821d41dd","type":"journal-article","created":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T12:22:17Z","timestamp":1307103737000},"page":"44-49","source":"Crossref","is-referenced-by-count":16,"title":["Polycythemia From Mast Cell Activation Syndrome: Lessons Learned"],"prefix":"10.1016","volume":"342","author":[{"given":"Lawrence B.","family":"Afrin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Lee","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0010","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1182\/blood-2007-12-128454","article-title":"The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal","volume":"112","author":"Spivak","year":"2008","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0015","series-title":"World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues.","year":"2001"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0020","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0025","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.amjmed.2008.01.001","article-title":"Overconfidence as a cause of diagnostic error in medicine","volume":"121","author":"Berner","year":"2008","journal-title":"Am J Med"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0030","first-page":"22","article-title":"Errors in clinical reasoning: causes and remedial strategies","volume":"339","author":"Scott","year":"2009","journal-title":"BMJ"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0035","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1309\/2EWQKN00PG02JKY0","article-title":"Bone marrow biopsies for the diagnosis of systemic mastocytosis: is one biopsy sufficient?","volume":"121","author":"Butterfield","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0040","series-title":"William textbook of endocrinology,","first-page":"1718","article-title":"Disorders of vasodilator hormones: carcinoid syndrome and mastocytosis","author":"Roberts","year":"1998"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0045","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1136\/thx.2004.026641","article-title":"Mast cell activation: monitoring mast cell activation by prostaglandin D2 in vivo","volume":"59","author":"Dahl\u00e9n","year":"2004","journal-title":"Thorax"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0050","doi-asserted-by":"crossref","first-page":"194","DOI":"10.7326\/0003-4819-59-2-194","article-title":"The mastocytosis syndrome: clinical and biological studies","volume":"59","author":"Demis","year":"1963","journal-title":"Ann Intern Med"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0055","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1369\/jhc.5A6739.2005","article-title":"Vesicular monoamine transporter 2 (VMAT2) expression in hematopoietic cells and in patients with systemic mastocytosis","volume":"54","author":"Anlauf","year":"2006","journal-title":"J Histochem Cytochem"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0060","doi-asserted-by":"crossref","first-page":"19S","DOI":"10.1111\/1523-1747.ep12468945","article-title":"Biochemical diagnosis of systemic mast cell disorders","volume":"96","author":"Roberts","year":"1991","journal-title":"J Invest Derm"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0065","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0070","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaci.2004.04.046","article-title":"The biology of Kit in disease and the application of pharmacogenetics","volume":"114","author":"Akin","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cyto.b.10072","article-title":"Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA)","author":"Escribano","year":"2004","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0085","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00251-010-0474-8","article-title":"Comparative analysis of mutation of tyrosine kinase Kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects","volume":"62","author":"Molderings","year":"2010","journal-title":"Immunogenetics"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0090","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood-2009-06-226027","article-title":"Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT phosphotransferase domain mutations","volume":"116","author":"Yang","year":"2010","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0095","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1182\/blood-2010-01-257287","article-title":"Mast cell proteases: multifaceted regulators of inflammatory disease","volume":"115","author":"Pejler","year":"2010","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0100","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1046\/j.0022-202x.2001.00029.x","article-title":"Mastocytosis: review of clinical and experimental aspects","volume":"6","author":"Hartmann","year":"2001","journal-title":"J Invest Derm Symp Proc"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1478-3231.2008.01839.x","article-title":"New aspects of liver abnormalities as part of the systemic mast cell activation syndrome","volume":"29","author":"Alfter","year":"2009","journal-title":"Liver Int"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0110","series-title":"COPE: cytokines and cells online pathfinder encyclopaedia","article-title":"Mast cells","author":"Ibelgaufts","year":"2011"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0115","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/978-1-4684-5344-7_73","article-title":"Mast cell pleomorphism: properties of intestinal mast cells","volume":"216A","author":"Swieter","year":"1987","journal-title":"Adv Exp Med Biol"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0120","series-title":"Sensitive and quantitative detection of KIT D816V in patients with systemic mastocytosis using allele specific real time PCR and digital PCR","author":"White","year":"2011"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0125","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2353\/jmoldx.2006.060022","article-title":"Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology","volume":"8","author":"Akin","year":"2006","journal-title":"J Mol Diagn"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0130","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0135","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.med.55.091902.103822","article-title":"Systemic mastocytosis","volume":"55","author":"Akin","year":"2004","journal-title":"Annu Rev Med"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0140","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KIT D816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0145","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/sj.leu.2403887","article-title":"The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107","volume":"19","author":"von Bubnoff","year":"2005","journal-title":"Leukemia"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0150","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","article-title":"Imatinib for systemic mast-cell disease","volume":"362","author":"Pardanani","year":"2003","journal-title":"Lancet"},{"key":"10.1097\/MAJ.0b013e31821d41dd_bb0155","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1097\/PAS.0b013e318078ce7a","article-title":"Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis","volume":"31","author":"Hahn","year":"2007","journal-title":"Am J Surg Pathol"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915312416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915312416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T07:36:06Z","timestamp":1560238566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915312416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0002962915312416"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e31821d41dd","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}